Amyloid and tau pathology are associated with cerebral blood flow in a mixed sample of nondemented older adults with and without vascular risk factors for Alzheimer's disease.
| Title: | Amyloid and tau pathology are associated with cerebral blood flow in a mixed sample of nondemented older adults with and without vascular risk factors for Alzheimer's disease. |
|---|---|
| Authors: | Swinford CG; Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA.; Risacher SL; Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA.; Vosmeier A; Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA.; Deardorff R; Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA.; Chumin EJ; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA; Indiana University Network Science Institute, Bloomington, IN, USA; Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA.; Dzemidzic M; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA; Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.; Wu YC; Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA.; Gao S; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA; Department of Biostatistics and Health Data Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.; McDonald BC; Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA; Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.; Yoder KK; Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA.; Unverzagt FW; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.; Wang S; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA; Department of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.; Farlow MR; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA; Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.; Brosch JR; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA; Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.; Clark DG; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA; Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA.; Apostolova LG; Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA; Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana University Network Science Institute, Bloomington, IN, USA.; Sims J; Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA.; Wang DJ; Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.; Saykin AJ; Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana Alzheimer's Disease Research Center, Indianapolis, IN, USA; Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA; Indiana University Network Science Institute, Bloomington, IN, USA. Electronic address: asaykin@iupui.edu. |
| Source: | Neurobiology of aging [Neurobiol Aging] 2023 Oct; Vol. 130, pp. 103-113. Date of Electronic Publication: 2023 Jun 28. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural |
| Language: | English |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 8100437 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1558-1497 (Electronic) Linking ISSN: 01974580 NLM ISO Abbreviation: Neurobiol Aging Subsets: MEDLINE |
| Imprint Name(s): | Publication: New York : Elsevier; Original Publication: Fayetteville, N.Y. : Ankho International. |
| MeSH Terms: | Alzheimer Disease*/pathology ; Cognitive Dysfunction*/diagnostic imaging; Cerebrovascular Circulation/physiology ; Aged ; Humans ; Amyloid beta-Peptides ; Amyloidogenic Proteins ; Biomarkers ; Magnetic Resonance Imaging ; Positron-Emission Tomography ; Risk Factors ; tau Proteins ; Amyloid beta-Protein Precursor |
| Abstract: | Identification of biomarkers for the early stages of Alzheimer's disease (AD) is an imperative step in developing effective treatments. Cerebral blood flow (CBF) is a potential early biomarker for AD; generally, older adults with AD have decreased CBF compared to normally aging peers. CBF deviates as the disease process and symptoms progress. However, further characterization of the relationships between CBF and AD risk factors and pathologies is still needed. We assessed the relationships between CBF quantified by arterial spin-labeled magnetic resonance imaging, hypertension, APOEε4, and tau and amyloid positron emission tomography in 77 older adults: cognitively normal, subjective cognitive decline, and mild cognitive impairment. Tau and amyloid aggregation were related to altered CBF, and some of these relationships were dependent on hypertension or APOEε4 status. Our findings suggest a complex relationship between risk factors, AD pathologies, and CBF that warrants future studies of CBF as a potential early biomarker for AD.; (Copyright © 2023 Elsevier Inc. All rights reserved.) |
| References: | Neurol Res. 2003 Sep;25(6):635-41. (PMID: 14503018); Mol Neurodegener. 2007 Apr 12;2:7. (PMID: 17430597); Magn Reson Med. 2003 Sep;50(3):599-607. (PMID: 12939768); J Neuropathol Exp Neurol. 2008 Apr;67(4):261-70. (PMID: 18379441); Alcohol Alcohol. 2022 Jul 9;57(4):445-451. (PMID: 34541599); Brain Imaging Behav. 2023 Apr;17(2):223-256. (PMID: 36484922); Sci Transl Med. 2011 Jun 29;3(89):89ra57. (PMID: 21715678); Biomed Pharmacother. 2010 Jul;64(6):430-6. (PMID: 20537498); Radiology. 2009 Mar;250(3):856-66. (PMID: 19164119); Circulation. 1998 May 12;97(18):1837-47. (PMID: 9603539); Am J Alzheimers Dis Other Demen. 2019 Aug;34(5):314-321. (PMID: 30966759); Alzheimers Dement. 2015 Jul;11(7):757-71. (PMID: 26194311); Ann Neurol. 1997 Jan;41(1):17-24. (PMID: 9005861); Alzheimers Dement. 2014 Nov;10(6):844-52. (PMID: 24798886); Brain. 2014 May;137(Pt 5):1550-61. (PMID: 24625697); J Magn Reson Imaging. 2020 Feb;51(2):505-513. (PMID: 31145515); Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1289-E1298. (PMID: 29358399); J Neurosci. 2020 Oct 28;40(44):8573-8586. (PMID: 33046556); Neurobiol Dis. 2019 Jun;126:124-136. (PMID: 30010004); Alzheimers Res Ther. 2017 Sep 12;9(1):71. (PMID: 28899416); Science. 2019 Jul 19;365(6450):. (PMID: 31221773); Neurology. 2005 Jan 25;64(2):277-81. (PMID: 15668425); J Nucl Med. 2000 Jan;41(1):57-64. (PMID: 10647605); Transl Stroke Res. 2015 Feb;6(1):69-77. (PMID: 25351177); Alzheimer Dis Assoc Disord. 2018 Oct-Dec;32(4):351-358. (PMID: 30376508); Nat Neurosci. 2020 Sep;23(9):1079-1089. (PMID: 32778793); Nat Rev Neurosci. 2004 May;5(5):347-60. (PMID: 15100718); Front Aging Neurosci. 2016 Jun 24;8:151. (PMID: 27445794); Brain Behav. 2012 May;2(3):221-30. (PMID: 22741095); Stroke. 2018 Aug;49(8):1969-1976. (PMID: 29991657); Neurodegener Dis. 2016;16(1-2):87-94. (PMID: 26560336); J Neurol Neurosurg Psychiatry. 2020 Dec;91(12):1316-1324. (PMID: 33046560); Brain. 2016 May;139(Pt 5):1539-50. (PMID: 26936940); Neurobiol Aging. 2021 Jun;102:111-118. (PMID: 33765424); Neurology. 2006 Sep 12;67(5):834-42. (PMID: 16966547); J Alzheimers Dis. 2014;42 Suppl 4:S411-9. (PMID: 25159672); Eur J Nucl Med Mol Imaging. 2020 Dec;47(13):3165-3175. (PMID: 32462397); Am J Physiol Heart Circ Physiol. 2002 Jul;283(1):H315-23. (PMID: 12063304); Nat Rev Neurol. 2018 Jul;14(7):399-415. (PMID: 29895964); Alzheimers Dement. 2021 Mar;17(3):327-406. (PMID: 33756057); Ageing Res Rev. 2021 Nov;71:101450. (PMID: 34419673); Exp Neurol. 2017 May;291:36-43. (PMID: 28161255); Dement Geriatr Cogn Disord. 2012;33(2-3):156-63. (PMID: 22722670); N Engl J Med. 2023 Jan 5;388(1):9-21. (PMID: 36449413); Proc Natl Acad Sci U S A. 2000 Sep 26;97(20):11050-5. (PMID: 10984517); J Cereb Blood Flow Metab. 2000 Dec;20(12):1659-68. (PMID: 11129782); Cogn Neurodyn. 2019 Dec;13(6):513-518. (PMID: 31741688); J Cereb Blood Flow Metab. 2016 Mar;36(3):581-95. (PMID: 26661143); Curr Opin Psychiatry. 2021 Mar 1;34(2):142-148. (PMID: 33395097); Magn Reson Med. 2015 Jan;73(1):102-16. (PMID: 24715426); J Alzheimers Dis. 2017;59(1):369-385. (PMID: 28671118); J Cereb Blood Flow Metab. 2016 Jan;36(1):241-52. (PMID: 25920959); Front Aging Neurosci. 2014 Mar 13;6:32. (PMID: 24659966); Am J Physiol Heart Circ Physiol. 2001 Dec;281(6):H2417-24. (PMID: 11709407); Front Aging Neurosci. 2017 Jan 11;8:321. (PMID: 28123366); Circ Res. 2019 Mar 29;124(7):1025-1044. (PMID: 30920929); Front Aging Neurosci. 2014 Jul 07;6:159. (PMID: 25071567); Ann Neurol. 2000 Jan;47(1):93-100. (PMID: 10632106); J Alzheimers Dis. 2020;73(1):87-101. (PMID: 31743999); Brain. 2016 May;139(Pt 5):1551-67. (PMID: 26962052); Am J Pathol. 2011 Oct;179(4):2001-15. (PMID: 21839061); Alzheimers Dement (Amst). 2021 Aug 24;13(1):e12230. (PMID: 34466653); Neurol Sci. 2015 May;36(5):707-12. (PMID: 25452168); Radiology. 2013 Apr;267(1):221-30. (PMID: 23238159); J Nucl Med. 2015 Aug;56(8):1199-205. (PMID: 26045309); Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5644-51. (PMID: 16567625); Stroke. 2004 Nov;35(11 Suppl 1):2620-2. (PMID: 15375299); Brain. 2020 Oct 1;143(10):3136-3150. (PMID: 33094327) |
| Grant Information: | T32 AG071444 United States AG NIA NIH HHS; R01 AG019771 United States AG NIA NIH HHS; R01 AG061111 United States AG NIA NIH HHS; R37 AG057739 United States AG NIA NIH HHS; U01 AG068057 United States AG NIA NIH HHS; U19 AG024904 United States AG NIA NIH HHS; R01 AG061788 United States AG NIA NIH HHS; P30 AG072976 United States AG NIA NIH HHS; R01 LM013463 United States LM NLM NIH HHS; U01 AG072177 United States AG NIA NIH HHS; P30 AG010133 United States AG NIA NIH HHS; U19 AG074879 United States AG NIA NIH HHS; U01 AG024904 United States AG NIA NIH HHS; K01 AG049050 United States AG NIA NIH HHS; R01 AG057739 United States AG NIA NIH HHS; R01 AG068193 United States AG NIA NIH HHS |
| Contributed Indexing: | Keywords: Amyloid PET; Arterial spin-labeled MRI; Biomarkers; Cerebral blood flow; Mild cognitive impairment; Tau PET |
| Substance Nomenclature: | 0 (Amyloid beta-Peptides); 0 (Amyloidogenic Proteins); 0 (Biomarkers); 0 (tau Proteins); 0 (MAPT protein, human); 0 (APP protein, human); 0 (Amyloid beta-Protein Precursor) |
| Entry Date(s): | Date Created: 20230727 Date Completed: 20230817 Latest Revision: 20260127 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC10529454 |
| DOI: | 10.1016/j.neurobiolaging.2023.06.014 |
| PMID: | 37499587 |
| Database: | MEDLINE |
Journal Article; Research Support, N.I.H., Extramural